FDA-Approved Ketamine Treatment Offers Hope for Depression Patients
Patients at a Long Island hospital report significant improvements with esketamine nasal spray, finding it more effective than traditional antidepressants.
Doctors at Mather Hospital on Long Island are utilizing FDA-approved ketamine treatments, specifically the esketamine nasal spray Spravato, to combat clinical depression. Patients in the program have reported rapid and significant improvements, with some stating it is more effective than long-term use of medications like Prozac.
Approximately 62% of the nearly 40 patients participating in the program at Mather Hospital have experienced symptom reduction. Ellen Talmage, a 66-year-old patient, described the treatment as life-changing. "I’m so much better that after this [interview], I’m picking up my daughter-in-law and the two grandbabies, and we’re going to the ocean," Talmage said.
She recounted previous struggles that limited her daily activities, such as needing anxiety medication for simple errands and being unable to attend events like concerts. "Anybody who’s had it for that long, you miss out on a lot of Christmases," she added.
Dr. Erin Dainer, chair of psychiatry at Mather Hospital in Port Jefferson, views the treatment as a potential breakthrough for managing depression. "From going to not being able to get out of bed and dress yourself to thinking about the future and having a job and having a purpose and meaning in life," Dainer stated. "I don’t see that with other treatments the way I do with this."
The treatment program involves a multi-week course, beginning with a low dose of 56 milligrams administered twice weekly under medical supervision. Doses are gradually increased based on patient response. Patients are monitored for two hours post-administration due to potential vivid reactions, which Talmage likened to a ride at an amusement park.
Unlike conventional antidepressants that target serotonin and norepinephrine, esketamine works by affecting NMDA receptors at a cellular level, influencing mood through a different biological pathway. Dr. Paniz Johari, a psychiatrist at Mather, believes esketamine will significantly impact the treatment of treatment-resistant depression within the next decade.
Mather Hospital staff acknowledge the stigma associated with ketamine, particularly outside of regulated medical settings. "Matthew Perry absolutely should never have happened," Dainer commented, referencing the actor's fatal overdose. "That’s why we have so many regulations with this medication because we want to ensure safety; we want to ensure efficacy."
Another anonymous patient shared that the ketamine treatment inspired him to pursue a career as a peer-to-peer counselor. "I think it’s a big thing between the ketamine and helping other people, that it gives you a purpose," he said.